Statin-induced myopathies (Q37946182)

25 August 2017

Statin-induced myopathies (English)

1 reference

25 August 2017

Stanisław Jerzy Czuczwar

series ordinal

4

object named as

Stanisław J Czuczwar

1 reference

25 August 2017

Michał Tomaszewski

1

1 reference

PubMed ID

22001973

25 August 2017

Karolina M Stępień

series ordinal

2

1 reference

PubMed ID

22001973

25 August 2017

Joanna Tomaszewska

series ordinal

3

1 reference

25 August 2017

1 January 2011

1 reference

25 August 2017

Pharmacological Reports

1 reference

25 August 2017

63

1 reference

25 August 2017

859-866

1 reference

25 August 2017

4

1 reference

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Resolution of statin-induced myalgias by correcting vitamin D deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Effect of coenzyme q10 on myopathic symptoms in patients treated with statins

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statin-induced apoptosis and skeletal myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Neuromuscular symptoms and elevated creatine kinase after statin withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Colchicine poisoning: the dark side of an ancient drug

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Benefit versus risk in statin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Outcomes in 45 patients with statin-associated myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Evidence-based management of statin myopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Individualising the risks of statins in men and women in England and Wales: population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Narrative review: statin-related myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Drug-induced myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Preventive effects of bicarbonate on cerivastatin-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Agents and mechanisms of toxic myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Muscle coenzyme Q10 level in statin-related myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statin safety: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statin myopathy: a review of recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

The role of coenzyme Q10 in statin-associated myopathy: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statin-associated myopathy and its exacerbation with exercise

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Effects of statins on nitric oxide/cGMP signaling in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Rhabdomyolysis induced by rosuvastatin and sildenafil.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

New insights into mechanisms of statin-associated myotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statins provoking MELAS syndrome. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Statin-associated myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Genetic predisposition to statin myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Genetic risk factors associated with lipid-lowering drug-induced myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970601-6

7 January 2021

10.1016/S1734-1140(11)70601-6

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22001973